Numinus Wellness Inc. (CA67054W1032)
XSTU 
Summary
Numinus Approved as a State-Certified Natural Medicine Training Program in Colorado
VANCOUVER, BC , March 20, 2025 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral health treatments including safe, evidence-based psychedelic-assisted therapies, is proud to announce that its Psychedelic-Assisted Therapy Training Program has been officially approved by the state of Colorado, marking a significant milestone in the company's mission to expand safe and effective psychedelic-assisted therapy. This approval comes as part of Colorado's Natural Medicine Health Act (Proposition 122), which establishes a legal framework for the facilitation of psilocybin services by trained and licensed professionals.
Numinus Wellness Inc. Announces CFO Transition
VANCOUVER, BC , Feb. 18, 2025 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral health treatments including safe, evidence-based psychedelic-assisted therapies, today announced a change in its Chief Financial Officer position. Effective February 18, 2025, Kelvin Yang will assume the role of Interim Chief Financial Officer, replacing Melony Valleau, who will be concluding her interim tenure at the end of February.
Numinus Wellness Inc. Announces Strategic Wind-Down of Non-Operating Subsidiaries
VANCOUVER, BC , Feb. 14, 2025 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23), a mental healthcare company advancing traditional and innovative behavioral health treatments including safe, evidence-based psychedelic-assisted therapies, today announced that its Board of Directors has approved the wind-down of certain non-operating subsidiaries as part of the Company's efforts to simplify its corporate structure and concentrate resources on its core business areas. This initiative is intended to enhance operational efficiency and financial sustainability.
Numinus Wellness Inc. Profile
| Medical - Care Facilities Industry | Healthcare Sector | Mr. Michael Tan M.B.A. CEO | XSTU Exchange | CA67054W1032 ISIN |
| CA Country | 200 Employees | - Last Dividend | 20 May 2020 Last Split | - IPO Date |
Overview
Numinus Wellness Inc. is at the forefront of integrating traditional mental health treatments with innovative psychedelic-assisted psychotherapy. With operations spanning across Canada and the United States, Numinus provides a comprehensive suite of services aimed at addressing a broad spectrum of mental health issues. The company distinguishes itself through its multifaceted approach which includes clinical research, a network of clinics in Canada and the U.S., and groundbreaking laboratory services focused on the development and application of psychedelic substances for therapeutic use. Founded in 1964 and headquartered in Vancouver, Canada, Numinus leverages its decades of experience to push the boundaries of mental wellness therapies.
Products and Services
Numinus Wellness Inc. offers a wide range of products and services designed to cater to various aspects of mental wellness and psychedelic-assisted therapy:
- Clinical Research Operations: This segment provides comprehensive clinical research management services tailored for academic institutions and biotechnology companies. It encompasses the development, execution, and supervision of clinical trials aimed at exploring the therapeutic potentials of psychedelics.
- Canadian Clinic Network: In Canada, Numinus operates a network of clinics delivering a diverse array of clinical services. These include but are not limited to traditional therapy and counseling, ketamine-assisted therapies specifically for depression, broader psychedelic-assisted therapies, mindfulness programs, virtual psychotherapy services, and neurological care. This holistic approach to mental health care underlines the company's commitment to innovative and accessible treatments.
- U.S. Clinic Network: Numinus extends its innovative approach to therapy into the United States, where its clinics offer similar psychedelic-assisted therapies. Additionally, services such as transcranial magnetic stimulation, psychiatric and medical model management further diversify the company's portfolio in the U.S., making varied and effective treatments more accessible to a wider audience.
- Laboratory Services: A pioneering facet of Numinus is its expansive laboratory operations. These encompass the cultivation, production, and extraction of Psilocybe and other psychoactive fungi species. The company is also engaged in the development of proprietary processes and products, controlled psychedelics protocols, and a product development pipeline. These efforts are complemented by an emphasis on safety, efficacy studies, and lab testing services. This robust infrastructure supports the company's research and therapeutic applications, ensuring high standards of quality and innovation.
- Psychedelic-Assisted Therapy Training Services: Recognizing the need for qualified practitioners in this emerging field of mental health care, Numinus offers specialized training for professionals. This program aims to equip therapists and medical practitioners with the necessary skills and knowledge to safely and effectively conduct psychedelic-assisted therapies, thereby ensuring the highest levels of care and patient outcomes.
Contact Information
